Survivin-△Ex3蛋白HLA-A2．1限制性CTL表位的基因疫苗抗肿瘤效果初探

摘要

To predict and synthesize HLA-A2.1 restricted survivin-△Ex3-derived CTL epitope gene vaccine,and discuss the protective effects of oral attenuated salmonella vaccine with epitope gene on the model mice of transplanted hepatic cellular cancer. Epitope gene sequences with highest scores in prediction were connected to establish eukaryotic expression vector of pVAX1 -STEs-EGFP,which was then transferred into the attenuated salmonella to act as oral vaccine.Experimental animals were divided into the control group (un-vaccinated),oral salmonella group ,oral attenuated salmonella group (transfected by pVAX1 plasmid),oral atten-uated salmonella group (transfected by pVAX1 -Survivin -△3 (T34A)-EGFP plasmid)and oral attenuated salmonella group (transfected by pVAX1 -STEs-EGFP plasmid).The mice were given immunization and then injected liver cancer cells subcutane-ously.The size of the mass at the injection site was measured.In 5 groups of the mice,the average diameters of the tumor were respec-tively 15.11 ±2.43 mm,13.70 ±2.97 mm,13.05 ±1.77 mm,7.46 ±2.61 mm and 9.05 ±2.18 mm;Epitope gene vaccine groups have significant difference when compared with the other groups (P<0.01 ).We concluded that HLA-A2.1 restricted surviving-△Ex3-derived CTL epitope gene vaccine can inhibit the proliferation and migration of mice liver cancer cells after oral administration to mice.%预测并合成survivin-△Ex3 HLA-A2．1限制性CTL表位的基因疫苗，探讨携带表位基因的减毒鼠伤寒沙门氏菌口服疫苗对小鼠移植肝癌模型的保护作用。将表位基因序列连接，构建pVAX1-STEs-EGFP真核表达载体，转化入减毒鼠伤寒沙门氏菌作为口服疫苗。实验动物分为未免疫对照组、口服沙门氏菌组、pVAX1质粒转染的减毒鼠伤寒沙门氏菌组；口服pVAX1-Survivin-△3（T34A）！ EGFP质粒转染的的减毒鼠伤寒沙门氏菌组和口服pVAX1-STEs ！ EGFP质粒转染的的减毒鼠伤寒沙门氏菌组。结果表明：在5组肿瘤模型小鼠中，肿瘤瘤块平均直径分别为：15．11±2．43 mm、13．70±2．97 mm、13．05±1．77 mm、7．46±2．61 mm、9．05±2．18 mm；表位疫苗组与其他组相比，有显著性差异（P＜0．01）。说明小鼠口服携带survivin-△Ex3 HLA-A2．1限制性CTL表位的基因疫苗后，能抑制小鼠肝癌细胞的增殖和扩散。